文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

重经治疗HIV感染者接受新型HIV衣壳抑制剂来那卡帕韦治疗2年后的耐药分析

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years.
PubMed 文献 · J Infect Dis · 2025-01-01

CAPELLA研究2年结果显示,来那卡帕韦联合优化背景方案使82%的重经治疗HIV-1感染者实现HIV-1 RNA抑制(缺失即排除)。19%(14/72)出现治疗 emergent 衣壳耐药,均与功能性来那卡帕韦单药治疗相关;7例耐药者恢复或更换优化背景方案后重新抑制。

要点

  • 来那卡帕韦联合优化背景方案治疗2年,82%重经治疗HIV-1感染者实现病毒抑制(缺失即排除)。
  • 19%(14/72)出现治疗 emergent 衣壳耐药,包括M66I、Q67H/K/N、K70H/N/R/S和/或N74D/H/K突变,均与功能性来那卡帕韦单药治疗相关。
  • 7例来那卡帕韦耐药者恢复或更换优化背景方案并继续来那卡帕韦治疗后重新达到HIV-1 RNA<50拷贝/mL。

核心结论

  • CAPELLA研究中2年来那卡帕韦耐药的出现是功能性来那卡帕韦单药治疗的结果。
  • 在一半来那卡帕韦耐药参与者中,继续来那卡帕韦联合有活性优化背景方案治疗导致HIV-1 RNA重新抑制。

研究设计与样本

  • 2/3期CAPELLA研究的事后耐药分析,纳入HIV-1 RNA可检测且对4大类药物中至少3类中每类≥2种药物耐药的的重经治疗HIV-1感染者。
  • 通过HIV-1衣壳、蛋白酶、逆转录酶和整合酶基因型/表型检测评估病毒学失败参与者的基线后耐药。
  • 通过液相色谱-串联质谱法测定血浆药物浓度评估优化背景方案依从性。

主要发现

  • 治疗2年后,来那卡帕韦联合优化背景方案使82%参与者实现HIV-1 RNA抑制(缺失即排除)。
  • 19%(14/72)参与者出现治疗 emergent 衣壳耐药,包括M66I、Q67H/K/N、K70H/N/R/S和/或N74D/H/K突变,均与功能性来那卡帕韦单药治疗相关。
  • 7例来那卡帕韦耐药参与者恢复或更换优化背景方案并继续来那卡帕韦治疗后重新达到HIV-1 RNA<50拷贝/mL。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lenacapavir is a highly potent first-in-class inhibitor of HIV-1 capsid that was approved for the treatment of heavily treatment-experienced people with HIV-1 harboring multidrug-resistant virus, and it is used in combination with an optimized background regimen (OBR). Resistance analyses conducted after 2 years of lenacapavir treatment in the phase 2/3 CAPELLA study are described. METHODS: CAPELLA enrollment consisted of viremic cases of heavily treatment-experienced people with HIV-1 and resistance to ≥2 drugs per class in at least 3 of the 4 main drug classes. Postbaseline resistance in participants experiencing virologic failure was evaluated by resistance assays (HIV-1 capsid, protease, reverse transcriptase, and integrase genotypic/phenotypic tests). Adherence to OBR was assessed by plasma drug measurement via liquid chromatography-tandem mass spectrometry. RESULTS: After 2 years, lenacapavir + OBR treatment led to HIV-1 RNA suppression in 82% of participants (missing = excluded). Treatment-emergent capsid resistance occurred in 19% (14/72) of participants, including capsid mutations M66I, Q67H/K/N, K70H/N/R/S, and/or N74D/H/K, which were all associated with functional lenacapavir monotherapy. Seven participants with lenacapavir resistance reattained HIV-1 RNA <50 copies/mL upon OBR resumption or change while maintaining lenacapavir treatment. CONCLUSIONS: Emergence of lenacapavir resistance after 2 years in CAPELLA was a consequence of functional lenacapavir monotherapy. In half of participants with lenacapavir resistance, continued treatment with lenacapavir + active OBR led to HIV-1 RNA resuppression.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Margot NA, Jogiraju V, Pennetzdorfer N, et al. Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years. J Infect Dis. 2025. PMID: 39873394. doi:10.1093/infdis/jiaf050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。